<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842633</url>
  </required_header>
  <id_info>
    <org_study_id>202172</org_study_id>
    <secondary_id>RH01649</secondary_id>
    <nct_id>NCT01842633</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache</brief_title>
  <official_title>A Study to Assess Efficacy Over Placebo and Speed of Onset of Pain Relief of New Paracetamol and Caffeine Tablets as Compared to Ibuprofen in Episodic Tension Type Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multi-center study is to assess the efficacy of headache relief of new
      paracetamol/caffeine formulation compared to placebo and ibuprofen in episodic tension-type
      headache (ETTH).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">April 1, 2013</start_date>
  <completion_date type="Actual">March 31, 2015</completion_date>
  <primary_completion_date type="Actual">March 31, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Difference (SPID) of Treatment and Placebo at 4 Hours</measure>
    <time_frame>Up to 4 hours post dose</time_frame>
    <description>SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 4 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180, 180-240 minutes. The range of SPID at 4 hours post dose was from -12 to 4&quot;. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Difference (SPID) at 1, 2 and 3 Hours</measure>
    <time_frame>From (Baseline) 0 to 1 hour, 0 to 2 hours, and 0 to 3 hours post dose</time_frame>
    <description>SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 1, 2 and 3 hours post dose.
The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60 minutes for SPID at 1 hour post dose. The range of SPID at 1 hour post dose was from -3 to 1. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120 minutes for SPID at 2 hours post dose . The range of SPID at 2 hours post dose was from -6 to 2. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180 minutes for SPID at 3 hours post dose. The range of SPID at 3 hours post dose was from -9 to 3. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perceptible Pain Relief</measure>
    <time_frame>Baseline up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Perceptible Headache Relief</measure>
    <time_frame>Baseline up to 4 hours</time_frame>
    <description>Time to perceptible headache relief was assessed as the time when participants achieve pain relief scores (PRS) more than or equal to 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Meaningful Pain Relief</measure>
    <time_frame>Baseline up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Meaningful Headache Relief</measure>
    <time_frame>Baseline up to 4 hours</time_frame>
    <description>Time to meaningful headache relief was assessed as time when participants reported a PRS â‰¥ 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR)</measure>
    <time_frame>From (Baseline) 0 to 1, from 0 to 2, from 0 to 3 and from 0 to 4 hour post dose</time_frame>
    <description>TOTPAR was calculated as the weighted sum of pain relief scores (PRS) at each time point. PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range for TOTPAR for different time points were as follows: from 0 to 4 for TOTPAR at 1 hour post dose, from 0 to 8 for TOTPAR at 2 hours post dose, from 0 to 12 for TOTPAR at 3 hours post dose, and from 0 to 16 for TOTPAR at 4 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Time-Response Curve for Change in Headache Intensity and Headache Relief (SPRID)</measure>
    <time_frame>From (Baseline) 0 to 1 hour, 0 to 2 hours, 0 to 3 hours and 0 to 4 hours post dose</time_frame>
    <description>SPRID was measured as sum of TOTPAR and SPID. SPID and TOTPAR were calculated as weighted sums of PID and PRS at each measurement time point, respectively. PID at each time point was calculated as difference of PI at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache). PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range of SPRID for different time points were as follow: from-3 to 5 for SPRID at 1 hour post dose, from -6 to 10 for SPRID at 2 hours post dose, from -9 to 15 for SPRID at 3 hours post dose, and from -12 to 20 for SPRID at 4 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation of Response to Treatment</measure>
    <time_frame>4 hours</time_frame>
    <description>Global evaluation of treatment response was measured by a score in a scale from: 0-very poor, 1-poor, 2-neutral [neither poor nor good], 3-good, or 4-very good).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Rescue Medication</measure>
    <time_frame>4 hours</time_frame>
    <description>Number of participants that took rescue medication over the total number of participants for a given treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Headache Pain Intensity</measure>
    <time_frame>At 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 min.</time_frame>
    <description>Change from baseline in headache pain intensity was calculated as the change (difference) from baseline PI with PI at each time-point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Relief</measure>
    <time_frame>At 10 min. 15 min., 20 min., 25 min., 30 min., 40 min., 50 min., 60 min., 90 min., 120 min., 180 min., 240 min.,</time_frame>
    <description>The participant assessed headache relief of each treated qualifying headache at 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 minutes post treatment on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). higher headache relief score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Pain Free Participants</measure>
    <time_frame>1 hour and 2 hour post dose</time_frame>
    <description>Number of participants with complete relief was calculated as the number of participants who reported PRS = 4-complete relief at 1 hour and 2 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the Use of Rescue Medication.</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Time taken by the participants to use the rescue medication</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Paracetamol/ Caffeine Caplets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen Caplets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two ibuprofen caplets plus two placebo caplets to be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Caplets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four placebo caplets to be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol and Caffeine</intervention_name>
    <description>Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine</description>
    <arm_group_label>Paracetamol/ Caffeine Caplets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Caplets containing 200 mg of ibuprofen</description>
    <arm_group_label>Ibuprofen Caplets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo caplets</description>
    <arm_group_label>Placebo Caplets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants in good general health, and with diagnosis of ETTH with following
             conditions:

               1. number of days with the condition is historically greater than or equal to two
                  per month;

               2. severity of headaches is historically at least moderate;

               3. duration of headaches is historically more than or equal to 4 hours, if
                  untreated.

                  Exclusion Criteria:

          -  Participant with known or suspected hypersensitivity, allergy, intolerance or
             contraindication to the use of any of the study medications

          -  Participant has chronic tension type headache, psychiatric disease or a significant
             cognitive disorder, or any chronic pain disorder.

          -  Participant currently taking or has taken medications or herbal supplements within the
             three months that are likely to interfere with the validity of subject-rated
             assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL International, LLC</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <results_first_submitted>June 2, 2016</results_first_submitted>
  <results_first_submitted_qc>June 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2017</results_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at clinical sites in the United States.</recruitment_details>
      <pre_assignment_details>365 participants were enrolled in the study out of which 165 participants were randomized in the study. 200 participants were not randomized for the following reasons: 165 were screening failure, 3 due to Adverse Events (AEs), 7 were lost to follow-up, 19 withdrawals by participant, and 6 due to other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Paracetamol/ Caffeine Caplets</title>
          <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65milligram (mg) plus 2 placebo caplets orally with 8 ounces of water</description>
        </group>
        <group group_id="P2">
          <title>Ibuprofen Caplets</title>
          <description>Participants were administered with two caplets of ibuprofen 200mg plus 2 placebo caplets orally with 8 ounces of water</description>
        </group>
        <group group_id="P3">
          <title>Placebo Caplets</title>
          <description>Participants were administered with four placebo caplets with 8 ounces of water</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical issues</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demography data is available for 157 Participants only (safety Population).</population>
      <group_list>
        <group group_id="B1">
          <title>Paracetamol/ Caffeine Caplets</title>
          <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus 2 placebo caplets orally with 8 ounces of water</description>
        </group>
        <group group_id="B2">
          <title>Ibuprofen Caplets</title>
          <description>Participants were administered with two caplets of ibuprofen 200mg plus 2 placebo caplets orally with 8 ounces of water</description>
        </group>
        <group group_id="B3">
          <title>Placebo Caplets</title>
          <description>Participants were administered with four placebo caplets orally with 8 ounces of water</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="11.39"/>
                    <measurement group_id="B2" value="38.1" spread="13.13"/>
                    <measurement group_id="B3" value="38.5" spread="12.65"/>
                    <measurement group_id="B4" value="38.9" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sum of Pain Intensity Difference (SPID) of Treatment and Placebo at 4 Hours</title>
        <description>SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 4 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180, 180-240 minutes. The range of SPID at 4 hours post dose was from -12 to 4&quot;. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).</description>
        <time_frame>Up to 4 hours post dose</time_frame>
        <population>Intention-to-treat (ITT) population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Difference (SPID) of Treatment and Placebo at 4 Hours</title>
          <description>SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 4 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180, 180-240 minutes. The range of SPID at 4 hours post dose was from -12 to 4&quot;. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).</description>
          <population>Intention-to-treat (ITT) population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.13" spread="2.164"/>
                    <measurement group_id="O2" value="-5.78" spread="2.098"/>
                    <measurement group_id="O3" value="-5.86" spread="2.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.36</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity Difference (SPID) at 1, 2 and 3 Hours</title>
        <description>SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 1, 2 and 3 hours post dose.
The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60 minutes for SPID at 1 hour post dose. The range of SPID at 1 hour post dose was from -3 to 1. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120 minutes for SPID at 2 hours post dose . The range of SPID at 2 hours post dose was from -6 to 2. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180 minutes for SPID at 3 hours post dose. The range of SPID at 3 hours post dose was from -9 to 3. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).</description>
        <time_frame>From (Baseline) 0 to 1 hour, 0 to 2 hours, and 0 to 3 hours post dose</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Difference (SPID) at 1, 2 and 3 Hours</title>
          <description>SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 1, 2 and 3 hours post dose.
The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60 minutes for SPID at 1 hour post dose. The range of SPID at 1 hour post dose was from -3 to 1. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120 minutes for SPID at 2 hours post dose . The range of SPID at 2 hours post dose was from -6 to 2. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180 minutes for SPID at 3 hours post dose. The range of SPID at 3 hours post dose was from -9 to 3. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 1 hour (n=62, 61, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.488"/>
                    <measurement group_id="O2" value="-0.56" spread="0.418"/>
                    <measurement group_id="O3" value="-0.57" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 hour (n=62, 61, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="1.106"/>
                    <measurement group_id="O2" value="-2.02" spread="1.002"/>
                    <measurement group_id="O3" value="-2.04" spread="1.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 hour (n=61, 62, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.09" spread="1.524"/>
                    <measurement group_id="O2" value="-3.86" spread="1.342"/>
                    <measurement group_id="O3" value="-3.97" spread="1.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perceptible Pain Relief</title>
        <time_frame>Baseline up to 4 hours</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perceptible Pain Relief</title>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of censored participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Perceptible Headache Relief</title>
        <description>Time to perceptible headache relief was assessed as the time when participants achieve pain relief scores (PRS) more than or equal to 1.</description>
        <time_frame>Baseline up to 4 hours</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Perceptible Headache Relief</title>
          <description>Time to perceptible headache relief was assessed as the time when participants achieve pain relief scores (PRS) more than or equal to 1.</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>minutes (min.)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.00" spread="31.274" lower_limit="6.0" upper_limit="140.3"/>
                    <measurement group_id="O2" value="29.67" spread="41.173" lower_limit="8.7" upper_limit="240.0"/>
                    <measurement group_id="O3" value="27.00" spread="38.042" lower_limit="4.0" upper_limit="156.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Meaningful Pain Relief</title>
        <time_frame>Baseline up to 4 hours</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Meaningful Pain Relief</title>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of censored participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Meaningful Headache Relief</title>
        <description>Time to meaningful headache relief was assessed as time when participants reported a PRS â‰¥ 2.</description>
        <time_frame>Baseline up to 4 hours</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Meaningful Headache Relief</title>
          <description>Time to meaningful headache relief was assessed as time when participants reported a PRS â‰¥ 2.</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>min.</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.33" spread="49.342" lower_limit="11.7" upper_limit="240.0"/>
                    <measurement group_id="O2" value="54.17" spread="49.095" lower_limit="16.7" upper_limit="240.0"/>
                    <measurement group_id="O3" value="46.67" spread="61.477" lower_limit="12.5" upper_limit="240.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief (TOTPAR)</title>
        <description>TOTPAR was calculated as the weighted sum of pain relief scores (PRS) at each time point. PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range for TOTPAR for different time points were as follows: from 0 to 4 for TOTPAR at 1 hour post dose, from 0 to 8 for TOTPAR at 2 hours post dose, from 0 to 12 for TOTPAR at 3 hours post dose, and from 0 to 16 for TOTPAR at 4 hours post dose.</description>
        <time_frame>From (Baseline) 0 to 1, from 0 to 2, from 0 to 3 and from 0 to 4 hour post dose</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief (TOTPAR)</title>
          <description>TOTPAR was calculated as the weighted sum of pain relief scores (PRS) at each time point. PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range for TOTPAR for different time points were as follows: from 0 to 4 for TOTPAR at 1 hour post dose, from 0 to 8 for TOTPAR at 2 hours post dose, from 0 to 12 for TOTPAR at 3 hours post dose, and from 0 to 16 for TOTPAR at 4 hours post dose.</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline-1 hour (62, 61, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.922"/>
                    <measurement group_id="O2" value="1.17" spread="0.801"/>
                    <measurement group_id="O3" value="1.14" spread="0.864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline-2 hour (62, 61, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="1.818"/>
                    <measurement group_id="O2" value="4.05" spread="1.740"/>
                    <measurement group_id="O3" value="3.82" spread="1.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline-3 hour (61, 62, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.84" spread="2.337"/>
                    <measurement group_id="O2" value="7.51" spread="2.250"/>
                    <measurement group_id="O3" value="7.35" spread="2.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline-4 hour (59, 59, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.57" spread="3.373"/>
                    <measurement group_id="O2" value="11.05" spread="3.774"/>
                    <measurement group_id="O3" value="10.47" spread="4.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Time-Response Curve for Change in Headache Intensity and Headache Relief (SPRID)</title>
        <description>SPRID was measured as sum of TOTPAR and SPID. SPID and TOTPAR were calculated as weighted sums of PID and PRS at each measurement time point, respectively. PID at each time point was calculated as difference of PI at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache). PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range of SPRID for different time points were as follow: from-3 to 5 for SPRID at 1 hour post dose, from -6 to 10 for SPRID at 2 hours post dose, from -9 to 15 for SPRID at 3 hours post dose, and from -12 to 20 for SPRID at 4 hours post dose.</description>
        <time_frame>From (Baseline) 0 to 1 hour, 0 to 2 hours, 0 to 3 hours and 0 to 4 hours post dose</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Time-Response Curve for Change in Headache Intensity and Headache Relief (SPRID)</title>
          <description>SPRID was measured as sum of TOTPAR and SPID. SPID and TOTPAR were calculated as weighted sums of PID and PRS at each measurement time point, respectively. PID at each time point was calculated as difference of PI at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache). PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range of SPRID for different time points were as follow: from-3 to 5 for SPRID at 1 hour post dose, from -6 to 10 for SPRID at 2 hours post dose, from -9 to 15 for SPRID at 3 hours post dose, and from -12 to 20 for SPRID at 4 hours post dose.</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 1 hour (n=62, 61, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.505"/>
                    <measurement group_id="O2" value="0.61" spread="0.424"/>
                    <measurement group_id="O3" value="0.57" spread="0.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 hour (n=62, 61, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="0.957"/>
                    <measurement group_id="O2" value="2.03" spread="0.933"/>
                    <measurement group_id="O3" value="1.78" spread="1.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 hour (n=61, 62, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="1.250"/>
                    <measurement group_id="O2" value="3.64" spread="1.285"/>
                    <measurement group_id="O3" value="3.38" spread="1.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4 hour (n=59, 59, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.44" spread="1.890"/>
                    <measurement group_id="O2" value="5.28" spread="2.126"/>
                    <measurement group_id="O3" value="4.61" spread="2.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Evaluation of Response to Treatment</title>
        <description>Global evaluation of treatment response was measured by a score in a scale from: 0-very poor, 1-poor, 2-neutral [neither poor nor good], 3-good, or 4-very good).</description>
        <time_frame>4 hours</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Global Evaluation of Response to Treatment</title>
          <description>Global evaluation of treatment response was measured by a score in a scale from: 0-very poor, 1-poor, 2-neutral [neither poor nor good], 3-good, or 4-very good).</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="0.740"/>
                    <measurement group_id="O2" value="2.81" spread="0.834"/>
                    <measurement group_id="O3" value="2.66" spread="0.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Rescue Medication</title>
        <description>Number of participants that took rescue medication over the total number of participants for a given treatment group</description>
        <time_frame>4 hours</time_frame>
        <population>ITT population defined as all participants who received treatment, who took rescue medication and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Rescue Medication</title>
          <description>Number of participants that took rescue medication over the total number of participants for a given treatment group</description>
          <population>ITT population defined as all participants who received treatment, who took rescue medication and who had at least one post-baseline efficacy assessment.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Headache Pain Intensity</title>
        <description>Change from baseline in headache pain intensity was calculated as the change (difference) from baseline PI with PI at each time-point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).</description>
        <time_frame>At 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 min.</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Headache Pain Intensity</title>
          <description>Change from baseline in headache pain intensity was calculated as the change (difference) from baseline PI with PI at each time-point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 10 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.166"/>
                    <measurement group_id="O2" value="-0.01" spread="0.064"/>
                    <measurement group_id="O3" value="-0.04" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 15 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.322"/>
                    <measurement group_id="O2" value="-0.06" spread="0.208"/>
                    <measurement group_id="O3" value="-0.10" spread="0.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 20 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.439"/>
                    <measurement group_id="O2" value="-0.21" spread="0.359"/>
                    <measurement group_id="O3" value="-0.21" spread="0.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 25 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.501"/>
                    <measurement group_id="O2" value="-0.34" spread="0.438"/>
                    <measurement group_id="O3" value="-0.36" spread="0.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 30 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.625"/>
                    <measurement group_id="O2" value="-0.51" spread="0.531"/>
                    <measurement group_id="O3" value="-0.55" spread="0.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 40 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.727"/>
                    <measurement group_id="O2" value="-0.75" spread="0.618"/>
                    <measurement group_id="O3" value="-0.75" spread="0.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 50 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.769"/>
                    <measurement group_id="O2" value="-0.93" spread="0.736"/>
                    <measurement group_id="O3" value="-0.96" spread="0.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 60 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="0.831"/>
                    <measurement group_id="O2" value="-1.17" spread="0.751"/>
                    <measurement group_id="O3" value="-1.14" spread="0.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 90 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.51" spread="0.748"/>
                    <measurement group_id="O2" value="-1.48" spread="0.708"/>
                    <measurement group_id="O3" value="-1.39" spread="0.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 120 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="0.704"/>
                    <measurement group_id="O2" value="-1.73" spread="0.727"/>
                    <measurement group_id="O3" value="-1.69" spread="0.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 180 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="0.529"/>
                    <measurement group_id="O2" value="-1.90" spread="0.530"/>
                    <measurement group_id="O3" value="-1.93" spread="0.561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 240 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="0.575"/>
                    <measurement group_id="O2" value="-1.91" spread="0.609"/>
                    <measurement group_id="O3" value="-1.95" spread="0.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Relief</title>
        <description>The participant assessed headache relief of each treated qualifying headache at 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 minutes post treatment on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). higher headache relief score indicates better outcome.</description>
        <time_frame>At 10 min. 15 min., 20 min., 25 min., 30 min., 40 min., 50 min., 60 min., 90 min., 120 min., 180 min., 240 min.,</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffiene Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Relief</title>
          <description>The participant assessed headache relief of each treated qualifying headache at 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 minutes post treatment on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). higher headache relief score indicates better outcome.</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.301"/>
                    <measurement group_id="O2" value="0.03" spread="0.140"/>
                    <measurement group_id="O3" value="0.11" spread="0.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.660"/>
                    <measurement group_id="O2" value="0.16" spread="0.374"/>
                    <measurement group_id="O3" value="0.27" spread="0.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.870"/>
                    <measurement group_id="O2" value="0.49" spread="0.670"/>
                    <measurement group_id="O3" value="0.60" spread="0.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.059"/>
                    <measurement group_id="O2" value="0.77" spread="0.870"/>
                    <measurement group_id="O3" value="0.88" spread="0.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="1.158"/>
                    <measurement group_id="O2" value="1.17" spread="1.072"/>
                    <measurement group_id="O3" value="1.22" spread="1.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="1.341"/>
                    <measurement group_id="O2" value="1.62" spread="1.195"/>
                    <measurement group_id="O3" value="1.49" spread="1.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="1.404"/>
                    <measurement group_id="O2" value="1.91" spread="1.356"/>
                    <measurement group_id="O3" value="1.82" spread="1.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="1.380"/>
                    <measurement group_id="O2" value="2.34" spread="1.255"/>
                    <measurement group_id="O3" value="2.14" spread="1.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="1.249"/>
                    <measurement group_id="O2" value="2.91" spread="1.162"/>
                    <measurement group_id="O3" value="2.68" spread="1.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="0.962"/>
                    <measurement group_id="O2" value="3.37" spread="1.113"/>
                    <measurement group_id="O3" value="3.03" spread="1.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="0.749"/>
                    <measurement group_id="O2" value="3.59" spread="0.907"/>
                    <measurement group_id="O3" value="3.44" spread="0.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="0.795"/>
                    <measurement group_id="O2" value="3.55" spread="1.138"/>
                    <measurement group_id="O3" value="3.32" spread="1.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Pain Free Participants</title>
        <description>Number of participants with complete relief was calculated as the number of participants who reported PRS = 4-complete relief at 1 hour and 2 hours post dose.</description>
        <time_frame>1 hour and 2 hour post dose</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pain Free Participants</title>
          <description>Number of participants with complete relief was calculated as the number of participants who reported PRS = 4-complete relief at 1 hour and 2 hours post dose.</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the Use of Rescue Medication.</title>
        <description>Time taken by the participants to use the rescue medication</description>
        <time_frame>Up to 4 hours</time_frame>
        <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol/ Caffeine Caplets</title>
            <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Caplets</title>
            <description>Participants were administered with two caplets of ibuprofen 200mg plus two placebo caplets orally with eight ounce of water</description>
          </group>
          <group group_id="O3">
            <title>Placebo Caplets</title>
            <description>Participants were administered with four placebo caplets orally with eight ounce of water</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the Use of Rescue Medication.</title>
          <description>Time taken by the participants to use the rescue medication</description>
          <population>ITT population defined as all participants who received treatment and who had at least one post-baseline efficacy assessment</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.00" spread="6.86"/>
                    <measurement group_id="O2" value="235.14" spread="24.06"/>
                    <measurement group_id="O3" value="235.55" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paracetamol/ Caffeine Caplets</title>
          <description>Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus 2 placebo caplets orally with 8 ounce of water</description>
        </group>
        <group group_id="E2">
          <title>Ibuprofen Caplets</title>
          <description>Participants were administered with two caplets of ibuprofen 200mg plus 2 placebo caplets orally with 8 ounce of water</description>
        </group>
        <group group_id="E3">
          <title>Placebo Caplets</title>
          <description>Participants were administered with four placebo caplets orally with 8 ounce of water</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEELING JITTERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>PARANASAL SINUS DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment into the trial was terminated after randomization of 62% of the plan resulting in a significant reduction in study power. The originally planned inferential statistics (p-values) were therefore not presented in tables summarizing results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

